GNW-Adhoc: BioNTech will publish results for the 2022 financial year on March 27, 2023 and provide information on operational progress in the fourth quarter

^MAINZ, Germany, March 13, 2023 (GLOBE NEWSWIRE) – BioNTech SE

( (Nasdaq: BNTX,?BioNTech” or?the company”) will be

Monday, March 27, 2023, the results of the financial year and the fourth

Release quarterly 2022. BioNTech will also be broadcast at 2:00 p.m. on the same day

MEZ to host a conference call and webcast with investment analysts to discuss the

Quarterly results and a corporate update for the fourth quarter and the

to present the entire financial year 2022 and invites investors as well as the

general public to participate.

To participate in the live conference call, please register via

this link

( After

You will be informed of the dial-in numbers including PIN when you register.

Please register at least one day in advance.

The presentation, including audio, will be streamed via this webcast link ( to be available.

A live webcast and presentation will also be available at

( under “Events & Presentations” in the

Investors section of the website made available. An audio recording of the

Presentation will be available on the website for 30 days after the end of the live webcast


About BioNTech

Biopharmaceutical New Technologies is an immunotherapy company

next generation that will help develop therapies for cancer and others

serious illnesses is doing pioneering work. The company combines a

Variety of modern therapeutic platforms and bioinformatics tools to

Rapidly advance the development of novel biopharmaceuticals. The

diversified portfolio of oncology product candidates

individualized therapies and off-the-shelf drugs based on mRNA,

innovative chimeric antigen receptor (CAR) T cells, bispecific checkpoint

Immunomodulators, Targeted Cancer Antibodies and Small Molecules. Based

its extensive expertise in the development of mRNA vaccines and

of in-house manufacturing capabilities, BioNTech is developing alongside its

diverse oncology pipeline together with collaboration partners

various mRNA vaccine candidates for a range of infectious diseases.

BioNTech works side by side with world-renowned cooperation partners

from the pharmaceutical industry, including Genmab, Sanofi, Genentech (a

Roche Group companies), Regeneron, Genevant, Fosun Pharma and Pfizer.

For more information, visit:



investor inquiries

Michael Horowicz

+1 (617) 955 7420

[email protected] (mailto:[email protected])

Media Inquiries

Jasmina Alatovic

+49 (0)6131 9084 1513

[email protected] (mailto:[email protected])


Selected Leverage Products on BioNTech (ADRs)With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the desired lever and we will show you suitable open-end products on BioNTech (ADRs)

Leverage must be between 2 and 20

No data